ArticleFrontiers in medicine2025
Re-sedation using remimazolam anesthesia in patients with multiple injuries during recovery: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
- Flumazenil reversal of remimazolam-induced sedation: a narrative review of safety, pharmacokinetics, and clinical considerations.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam combined with flumazenil can shorten recovery time, but the occurrence of re-sedation may put the patient at risk. Herein, we report a case of a 50-year-old woman who underwent general anesthesia using remimazolam. During emergence from general anesthesia, she briefly regained consciousness after receiving 0.4 mg of flumazenil and then fell unconscious again. The disturbance of consciousness lasted for 75 min. We diagnosed re-sedation after ruling out other possible causes. We simulated anesthetic concentration changes using TIVA trainer software, further confirming re-sedation through mechanistic analysis. Additionally, we reviewed the literature and analyzed the potential reasons for the occurrence of re-sedation under various conditions. The occurrence of re-sedation is not only related to the administration of flumazenil but also to individual differences in the effect-site concentration of remimazolam and the phenomenon of rapid tolerance. In clinical practice, flumazenil should be used cautiously, avoiding single high-dose administration, and considering delayed administration when appropriate. For critically ill patients, clinicians should closely monitor and guard against the occurrence of re-sedation. Further research is needed to determine the optimal time to administer flumazenil and to identify the demographic and clinical characteristics of patients who experience re-sedation, thereby guiding patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.